WuXi XDC Cayman Inc 02268
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- HK$76.15
- Day Range
- HK$68.50–76.95
- 52-Week Range
- HK$43.50–85.60
- Bid/Ask
- HK$68.85 / HK$68.90
- Shares Outstanding
- 1.27B
- Market Cap
- HK$87.25B
- Volume/Avg
- 9M / 7M
Key Statistics
- Price/Earnings (Normalized)
- 47.42
- Price/Sales
- 12.06
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Large Growth
- Total Number of Employees
- 3,628
- Website
- https://www.wuxixdc.com
Valuation
|
Metric
|
02268
|
|---|---|
Price/Earnings (Normalized) | 47.42 |
Price/Book Value | 6.90 |
Price/Sales | 12.06 |
Price/Cash Flow | 35.66 |
Price/Earnings
02268
Financial Strength
|
Metric
|
02268
|
|---|---|
Quick Ratio | 2.27 |
Current Ratio | 2.46 |
Interest Coverage | 83.69 |
Quick Ratio
02268
Profitability
|
Metric
|
02268
|
|---|---|
Return on Assets (Normalized) | 13.20% |
Return on Equity (Normalized) | 18.78% |
Return on Invested Capital (Normalized) | 15.11% |
Return on Assets
02268
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|XMx^N@!p | LOCK|f! | $257B | |||
| Danaher Corp
DHR
| LOCK|^^$^d^& | LOCK|!gj | $164B | |||
| Agilent Technologies Inc
A
| LOCK|xfk@#My? | LOCK|s? | $50B | |||
| IQVIA Holdings Inc
IQV
| LOCK|?t$z?%p | LOCK|y&hz | $46B | |||
| Waters Corp
WAT
| LOCK|QN%tHP | LOCK|Hk | $45B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|>%Vj#<rG | LOCK|!Y | $44B | |||
| Illumina Inc
ILMN
| LOCK|hkbQl?& | LOCK|!T>^ | $43B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|$n&Tr#R | LOCK|@^kfg | $34B | |||
| Quest Diagnostics Inc
DGX
| LOCK|%^PJDc | LOCK|Kl<!g | $26B | |||
| Labcorp Holdings Inc
LH
| LOCK|#F<KZySy | LOCK|clzF! | $26B |
United States